Gabapentin Capsule
Product Images NDC 71610-126

Product Visual Gallery

This gallery contains 8 technical images submitted to the FDA as part of the official labeling for Gabapentin (NDC 71610-126). Unlike standard consumer photos, these assets often include clinical data figures, molecular chemical structures, and official manufacturer packaging layouts.

As provided by Aphena Pharma Solutions - Tennessee, Llc, these visuals offer a comprehensive scientific overview of the product's physical and chemical identity, aiding pharmacists and researchers in product verification and study.

FDA Label Image

Bottle Label 100 mg (71610 0126 60)

This appears to be a prescription label for Gabapentin medication. The medication comes in capsule form with a strength of 100mg and the prescription includes 90 capsules. Unfortunately, no further information is available to provide a more detailed description.*

FDA Label Image

Aphena Pharma Solutions (TN)

FDA Label Image

Formula (Gabapentin Fig1)

This text appears to be a formula for calculating Lt (probably a medical measurement). It suggests multiplying the patient's age in years by their weight in kilograms, and then multiplying the result by a value given for creatinine (0.85 for female patients). However, without further context, it is difficult to determine the purpose or significance of this formula.*

FDA Label Image

Figure 1 (Gabapentin Fig2)

This is a graph showing the mean pain score over a period of 7 weeks in a study evaluating the effectiveness of Gabapentin compared to a placebo. The dose titration period was not specified, but there was a 4-week fixed dose period. The mean pain score was 10 at baseline and at weeks 1-7.*

FDA Label Image

Figure 2 (Gabapentin Fig3)

FDA Label Image

Figure 3 (Gabapentin Fig4)

The text seems to be part of a research study report on patients with Postherpetic neuralgia (PHN). The text presents the percentage of patients that had a reduction in pain score and the results of a controlled study with Placebo and GBP (Gabapentin) at different doses. The symbol #p<001 suggests that the differences between the placebo and GBP groups are statistically significant. Overall, without further context, it is difficult to draw further conclusions.*

FDA Label Image

Figure 4. Responder Rate In Patients Receiving Gabapentin Expressed As A Difference From Placebo By Dose And Study: Adjunctive Therapy Studies In Patients ≥12 Years Of Age With Partial Seizures (Gabapentin Fig5)

FDA Label Image

Chemical Structure (Gabapentin Str)

* These product label images have been analyzed using experimental machine learning. Please verify findings with the primary label text.